Skip to content

Systemic effects in patients with COPD; training or treatment

Systemic effects in patients with COPD; training or treatment - Systemic effects in patients with COPD

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON30383
Enrollment
42
Registered
2006-12-08
Start date
2006-11-01
Completion date
Unknown
Last updated
2024-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic obstructive pulmonary disease

Interventions

We study the influence of n-acetylcysteine and rosuvastatin on the parameters of systemic inflammation, oxidative stress and muscle breakdown in bloodsamples of muscle depleted COPD patients, before

Sponsors

Universitair Medisch Centrum Sint Radboud
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: clinically stable COPD patients (GOLD II, III, IV) with a low fat-free mass (

Exclusion criteria

Exclusion criteria: Exacerbation less than 2 months before the start of the experiment Smoking Oral corticosteroids Long-term oxygen therapy Respiratory insufficiency (PaO2 6,3 kPa) Other chronic exercise limiting disorders

Design outcomes

Primary

MeasureTime frame
Differences in parameters of systemic inflammation (concentrations of leukocyts, CRP, IL-6, IL-8, IL-1ra, TNFa) after intervention. Differences in parameters of oxidative stress (ROS-production, plasma antioxidant capacity, protein oxidation, lipid peroxidation, GSSG/GSH-ratio) after intervention. Differences in parameters of muscle damage (troponin I) after intervention. Differences in parameters of muscle breakdown (ubiquitin-proteasome system). Differences in pulmonary parameters and exercise capacity.

Secondary

MeasureTime frame
-

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)